Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research: January 15, 2009; Volume 69, Issue 2, Supplement 1
doi: 10.1158/0008-5472.SABCS-3080
CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts
© 2009 American Association for Cancer Research
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Nair, H.
Right arrow Articles by Tekmal, R.
PubMed
Right arrow Articles by Nair, H.
Right arrow Articles by Tekmal, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Delicious   Add to Digg  
What's this?

Novel / Emerging Therapeutic Targets

Nano-gossypin, a novel cdk2/VEGF inhibitor formulation against breast cancer.

HB Nair1, P Veerapaneni1, DM Sophie1, NB Kirma1, RP Perla1 and RR Tekmal1

1 Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX

Abstract

Abstract #3080

Cyclin-dependent kinases (CDKs) play essential roles in the intracellular control of the cell cycle. The encapsulated therapeutic drug molecules as nanoparticles will offer a sustained delivery of chemotherapeutics in to the target tissue. Nanoparticles enhance the therapeutic efficacy of an encapsulated drug by increased and sustained delivery of the drug inside the cell. Most anticancer drugs are taken up non-specifically by all types of cells, resulting in serious side-effects. Therefore, an ideal delivery carrier for an anticancer drug should be able to transport the drug specifically to cancer cells and release the drug molecules inside the cells to the site of their pharmacological activities. Most of the activity proven natural products were not entered in to the clinical practice due to lack of active formulation and/ or effective targeted delivery systems. In our study we found that gossypin (3,5,7,3',4'-Pentahydroxy-8-O-glucosylflavone) is inhibiting cell cycle progression by inhibiting cyclin dependent kinase-2 (cdk2) when compared with roscovitine, a known cdk2 inhibitor. Gossypin has been shown to induce the accumulation of the tumor suppressor p53, cell cycle arrest in G1 and G2/M phases of the cell cycle, and to induce apoptosis in MCF-7, SKBR-3, and MDA-MB-231 cells with a mean IC 50 of 40uM. Gossypin also found to inhibit vascular endothelial growth factor (VEGF) in vitro. Nanoparticle formulation of gossypin effectively inhibited the growth and colony formation in vitro when compared to parent compound. Gossypin might exert inhibition of tumor cell growth and invasion by cell cycle arrest as well as VEGF induced vascular permeability and tumor neovascularization. The dual mode of action of gossypin may results in highly efficacious inhibition of tumor growth and management of breast cancer.

Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3080.





This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Nair, H.
Right arrow Articles by Tekmal, R.
PubMed
Right arrow Articles by Nair, H.
Right arrow Articles by Tekmal, R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Delicious   Add to Digg  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.